- Trial phase
- Approved
- Time to market
- Already approved and marketed; first approved in the 1980s.
- Why 3/10
- Sulperazon is an already-approved, marketed antibiotic with no scheduled PDUFA date, pivotal readout, or other hard binary catalyst in the next 12 months. It is a mature, off-patent product that represents a negligible portion of Pfizer's $62B+ annual revenue, so no single event is likely to drive a material share-price move.
Sulperazon is a mature, off-patent antibiotic with no upcoming regulatory catalysts or clinical readouts. For Pfizer investors, this drug is not a material value driver; the stock's performance will be determined by Pfizer's pipeline (vaccines, oncology, mRNA) and overall revenue trends, not this legacy product.
Price Chart
Executive Summary
Sulperazon is Pfizer's brand name for cefoperazone/sulbactam, a combination antibiotic used to treat serious bacterial infections. It is an already-approved, off-patent product that has been on the market for decades and is sold primarily outside the United States (the individual component cefoperazone was discontinued in the US). The global market for Sulperazon is estimated at roughly $477-730 million annually, a tiny fraction of Pfizer's $62+ billion in total revenue. There are no pending regulatory decisions, pivotal clinical readouts, or other binary catalysts for this drug. For a Pfizer investor, Sulperazon is a mature legacy product with steady but unexciting dynamics and essentially zero impact on the stock's trajectory.
How It Works
Sulperazon is a combination of two drugs: cefoperazone (a cephalosporin antibiotic that kills bacteria by disrupting their cell wall construction) and sulbactam (a beta-lactamase inhibitor that prevents bacteria from breaking down the antibiotic). Together, they treat a range of bacterial infections including urinary tract, respiratory, intra-abdominal, and skin infections.
Trial Status
Sulperazon is an approved, marketed drug. No new clinical trials for this combination were found in the SecBot pipeline database for the past year. Academic research continues on optimized dosing regimens, but no registrational or pivotal trials are underway.
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory or clinical catalysts identified for Sulperazon specifically.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report